Emergent Biosolutions agrees $23.4 million US government anthrax contract
This article was originally published in Scrip
Executive Summary
Emergent BioSolutionsis to receive up to $23.4 million in US government funding to develop its anthrax monoclonal antibody AVP-21D9. The four-year contract, awarded by the Department of Health and Human Services, will provide funding for the scale-up of manufacturing processes, non-clinical studies and a Phase I trial for the anthrax candidate.